Pharmaceuticals

Successfully navigating the stock market requires patience and a long-term perspective. The key is to stick to a consistent plan and make regular contributions to a retirement account, allowing the power of compounding to work its magic…

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire…

In a recent deal, Hongbo Lu, a director at Terns Pharmaceuticals, Inc. (NASDAQ:TERN), bought a significant amount of the company’s stock, signaling a strong vote of confidence in the company’s future prospects. The deal, which closed on…

Lexicon Pharmaceuticals (NASDAQ: NASDAQ:) reported in their second quarter 2024 earnings call a modest growth in their INPEFA business and a net loss of $53.4 million. The company highlighted the resubmission of their New Drug Application…

Medexus Pharmaceuticals (MDP.V) has announced a record revenue of $113.1 million for the fiscal year 2024, along with a positive adjusted EBITDA of $19.5 million. Despite a decrease in revenue and gross profit for the fourth quarter, the…

Washington, May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:) Vanda (Nasdaq: VNDA) announced today that the company will participate in the Jefferies 2024 Global Healthcare Conference in... New York City on Thursday, June…

- Seven summaries highlighting ALGS and PFIC data, including three oral presentations- Long-term extension data from the phase III PFIC study were presented in plenary and selected from among the highest-scoring abstracts FOSTER CITY,…

Vertex Pharmaceuticals (NASDAQ:), a leading biotechnology firm, has been under the Wall Street microscope as analysts weigh in on the company's prospects, particularly in light of its expanding pipeline beyond its stronghold…

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire…

© Reuters Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring…